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vemurafenib plus cobimetinib in previously
untreated metastatic melanoma patients
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Abstract
Background: Metastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest
growing global incidence rate of all malignancies. The introduction of BRAF/MEK inhibitor combinations has yielded
significant increases in PFS and OS for melanoma. However, at present, no direct comparisons between different
BRAF/MEK combinations have been conducted. In light of this, an indirect treatment comparison was performed
between two BRAF/MEK inhibitor combination therapies for metastatic melanoma, dabrafenib plus trametinib and
vemurafenib plus cobimetinib, in order to understand the relative efficacy and toxicity profiles of these therapies.
Methods: A systematic literature search identified two randomized trials as suitable for indirect comparison: the
coBRIM trial of vemurafenib plus cobimetinib versus vemurafenib and the COMBI-v trial of dabrafenib plus trametinib
versus vemurafenib. The comparison followed the method of Bucher et al. and analyzed both efficacy (overall survival
[OS], progression-free survival [PFS], and overall response rate [ORR]) and safety outcomes (adverse events [AEs]).
Results: The indirect comparison revealed similar efficacy outcomes between both therapies, with no statistically
significant difference between therapies for OS (hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.68 − 1.30), PFS (HR
1.05, 95% CI 0.79 − 1.40), or ORR (risk ratio [RR] 0.90, 95% CI 0.74 − 1.10). Dabrafenib plus trametinib differed significantly
from vemurafenib plus cobimetinib with regard to the incidence of treatment-related AE (RR 0.92, 95% CI 0.87 − 0.97),
any AE grade ≥3 (RR 0.71, 95% CI 0.60 − 0.85) or dose interruption/modification (RR 0.77, 95% CI 0.60 − 0.99). Several
categories of AEs occurred significantly more frequently with vemurafenib plus cobimetinib, while some occurred
significantly more frequently with dabrafenib plus trametinib. For severe AEs (grade 3 or above), four occurred significantly
more frequently with vemurafenib plus cobimetinib and no severe AE occurred significantly more frequently with
dabrafenib plus trametinib.
Conclusions: This indirect treatment comparison suggested that dabrafenib plus trametinib had comparable efficacy to
vemurafenib plus cobimetinib but was associated with reduced adverse events.
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Background
Metastatic melanoma is an uncommon but aggressive
form of skin cancer, with a high mortality rate [1, 2].
Although melanoma represents less than 5% of all diag-
nosed skin cancers, the World Health Organization has
indicated that its incidence is increasing faster than any
other type of malignancy, mainly due to the general pop-
ulation’s increasing exposure to ultraviolet light [3–5].
Estimates put new diagnoses of melanoma at 132,000
globally in 2015 [3, 5]. The year-on-year increase in glo-
bal incidence of melanoma is estimated to be between 3
and 7%; based on these estimates, thus a doubling in the
incidence of melanoma occurs every 10–20 years [3].
Up to 70% of patients diagnosed with melanoma and
approximately 50% of patients with the advanced form
of melanoma possess a mutation in the BRAF gene,
leading to aberrant activation of the mitogen-activated
protein kinase (MAPK) pathway, a well-documented
cancer pathway [6–9]. Patients with distant metastases
and a BRAF mutation have significantly reduced median
overall survival (OS) when compared with patients with
distant metastases and BRAF wild-type [10]. These attri-
butes have provided the impetus for significant drug
development efforts that target BRAF-mutated meta-
static melanoma.
The introduction of BRAF inhibitors such as vemura-
fenib and dabrafenib have yielded significantly improved
outcomes in patients with metastatic melanoma with
either BRAF V600E or V600K mutations [11, 12].
However, BRAF inhibitors have substantial therapeutic
disadvantages. Acquired resistance to such inhibitors fre-
quently develops due to reactivation of the MAPK path-
way. This reactivation occurs primarily through three
mechanisms: mutations in the upstream RAS proteins,
mutant BRAF amplification, and alternative splicing
mechanisms [9, 13]. This acquired resistance limits the
median progression-free survival (PFS) and OS achiev-
able with BRAF inhibitors to 6–8 months [14, 15]. In
addition, the use of BRAF inhibitors may result in the
development of secondary skin cancer, further limiting the
therapeutic benefit of this monotherapy [11, 13, 16–20].
The addition of a MEK inhibitor along with a BRAF
inhibitor can combat the BRAF inhibitor-related resist-
ance and side effects that occur during monotherapy.
This combination therapy has demonstrated an increase
in median PFS and OS, along with a decrease in the inci-
dence of BRAF-inhibited induced skin tumors [10, 16, 21].
The 2015 United States and European guidelines recom-
mend the use of dabrafenib plus trametinib for metastatic
melanoma patients with a BRAF V600 mutation [22, 23].
More recently, the Food and Drug Administration in the
United States and European Medicines Agency have
approved vemurafenib plus cobimetinib as a combin-
ation therapy for patients with BRAF V600E or
V600K mutation-positive unresectable or metastatic
melanoma [24, 25].
In the absence of evidence from head-to-head trials
providing a direct comparison of treatments, health
technology assessment agencies require an indirect com-
parison to help them in their evaluations. In addition,
these types of comparisons can inform therapeutic deci-
sions. Srivastava et al. in 2015 published an indirect
treatment comparison (ITC) of dabrafenib versus vemur-
afenib, showing that both dabrafenib and trametinib
monotherapies demonstrated comparable PFS and OS,
and different tolerability and safety profiles, when indir-
ectly compared with vemurafenib [26].
The objective of this study was to conduct an ITC
between two common BRAF/MEK inhibitor combina-
tions, dabrafenib plus trametinib and vemurafenib plus
cobimetinib, in patients with metastatic melanoma with-
out prior therapy for the metastatic disease stage in
order to further understand the therapeutic and toler-
ability profile of these therapies.
Methods
A systematic literature review was conducted to identify
published studies that would permit an ITC between
dabrafenib plus trametinib and vemurafenib plus cobi-
metinib. From the literature review, two studies were
identified that would support an ITC of dabrafenib plus
trametinib versus vemurafenib plus cobimetinib using
vemurafenib as a common comparator: COMBI-v, an
international, open-label, randomized, Phase 3 trial of
dabrafenib plus trametinib versus vemurafenib mono-
therapy in previously untreated patients with unresect-
able stage IIIC or IV melanoma with BRAF V600E or
V600K mutations [27] and coBRIM, an international,
multicenter, randomized Phase 3 trial of cobimetinib
plus vemurafenib versus vemurafenib plus placebo in
previously untreated patients with advanced BRAF-
mutated melanoma [21] (Fig. 1). In both trials, vemura-
fenib 960 mg orally twice daily was administered in the
control arm.
The ITC was conducted using the methodology
described by Bucher et al. [28]. The method outlined by
Bucher et al. in 1997 relies on the principle that the log
of the effect size measured for drug A versus drug B is
Fig. 1 Network diagram for the indirect comparison of trametinib
with vemurafenib
Daud et al. Journal of Hematology & Oncology  (2017) 10:3 Page 2 of 9
equal to the difference of the log effect size measures for
drug A versus drug C and drug B versus drug C [28].
This holds true for both dichotomous outcomes, where
risk ratios (RRs) and odds ratios can be used as the
effect size measure, and time-to-event outcomes, where
hazard ratios (HRs) can be used as the effect size meas-
ure. The principal assumption of the model proposed by
Bucher et al. is that the relative efficacy of a treatment is
the same in all trials included in the indirect compari-
son, meaning that if A and B are compared in two or
more trials, then the effect size of A versus B is similar
across all the trials [28]. Further, this method assumes
independence between pairwise comparisons, i.e., the
comparison of A versus B is independent of the com-
parison of B versus C [28].
The trials included in the ITC were qualitatively
assessed for their patient population in terms of disease
characteristics, disease stage, severity of disease, and
patient characteristics. Additional subgroup analyses
were conducted in cases where a difference in a patient
baseline characteristic between the two trial populations
was considered potentially clinically meaningful.
The efficacy outcomes that were assessed were overall
response rate (ORR), PFS, and OS. The primary efficacy
outcome was OS in the COMBI-v trial and PFS in the
coBRIM trial. The secondary efficacy outcomes were
PFS and ORR in the COMBI-v trial and ORR and OS in
the coBRIM trial. Safety was assessed as a secondary
endpoint in both of the trials. Multiple data sources in-
cluding both published and unpublished sources were
utilized to retrieve efficacy and safety data for the
COMBI-v and coBRIM trials (Table 1).
The primary ITC for OS and PFS was based on the
most recent data cut-off dates; March 2015 for COMBI-v
[29] and August 2015 for coBRIM [30] (Table 1). The pri-
mary ITC for ORR was based on the April 2014 data cut-
off for COMBI-v and the January 2015 data cut-off for
coBRIM (Table 1). Of note, crossover was permitted in
COMBI-v, following the recommendation by the Inde-
pendent Data Monitoring Committee (IDMC) based on
the planned interim results, whereas no crossover was
permitted in coBRIM. The interim analysis was conducted
using COMBI-v at the cut-off date of April 2014. To as-
sess whether the crossover might have confounded OS
Table 1 Sources and data cut-offs used in primary and additional ITCs
Outcome COMBI-v coBRIM
Data cut-off Data source Data cut-off Data source
Efficacy outcomes
OS Primary Analysis —March 2015
Additional analysis
(without crossover)—April 2014
Additional analysis
(LDH subgroups)—March 2015
Robert 2015b [29]
Robert 2015a [27]
Novartis Pharmaceuticals
Corporation, unpublished
observations
August 2015 Atkinson 2015 [30]
PFS Primary analysis—March 2015 Robert 2015b [29] January 2015 Larkin 2015c [32]
Additional analysis
LDH subgroups—April 2014
Novartis Pharmaceuticals
Corporation, unpublished
observations
ORR April 2014 Robert 2015a [27] January 2015 Larkin 2015c [32]
General adverse events
Any AE, any SAE, discontinuation
due to AE, AE leading to death,
any grade ≥3 AE
March 2015 Robert 2015b [29]
and Novartis Pharmaceuticals
Corporation, unpublished
observations
September 2014 EMA label [33, 34]
Any treatment-related AE, any
dose interruptions/modifications
April 2014 Robert 2015a [27]
Specific adverse events
All specific adverse events except
those highlighted in the row below
March 2015 Robert 2015b [29]
and Novartis Pharmaceuticals
Corporation, unpublished
observations
September 2014 EMA label
Keratocanthoma May 2014 Larkin 2014 [21]
CuSCC—all grades April 2014
Chills—all grades grade 3 to 5:
alopecia, nausea, pyrexia, vomiting
March 2015 May 2014 EMA label
AE Adverse event, CuSS cutaneous squamous cell carcinoma, D + T dabrafenib plus trametinib, ECOG Eastern Cooperative Oncology Group, EMA European
Medicines Agency, ITC Indirect treatment comparison, LDH lactate dehydrogenase, OS Overall survival, ORR Overall response rate, PFS Progression-free survival,
SAE Severe adverse event, V vemurafenib, V + C vemurafenib plus cobimetinib
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results of the primary ITC, an additional ITC for OS was
conducted using the COMBI-v interim data cut-off of
April 2014, the point at which no patients had crossed
over, and the August 2015 cut-off for coBRIM.
Two other additional ITCs were conducted for OS and
PFS in two subgroup populations, i.e., patients with nor-
mal and elevated lactate dehydrogenase (LDH) levels, to
assess the impact of any variation in the baseline LDH
levels on the primary ITC results.
The effect sizes for indirect comparisons were calcu-
lated using the methodologies proposed by Bucher et al.
[28]. The 95% confidence interval (CI) values and p values
for the effect sizes were calculated using Cochran-Mantel-
Haenszel statistics. All calculations were conducted using
STATA® software (version 11).
Results
The baseline epidemiological and disease characteristics
of the patient cohorts in the COMBI-v and coBRIM
studies have been reported previously and are summa-
rized in Table 2 [21, 27]. Baseline patient characteristics,
including known prognostic factors, were generally well
balanced in all the treatment arms of both studies, ex-
cept that slightly more patients in the coBRIM trial had
elevated serum LDH at baseline. Thirty-three percent of
patients presented with elevated LDH levels (dabrafenib
plus trametinib [34%] and vemurafenib [32%]) in the
COMBI-v trial, while the coBRIM trial had 46% of pa-
tients with elevated LDH levels (vemurafenib plus cobi-
metinib [46%] and vemurafenib [43%]).
Efficacy
In the primary ITC, the HR (for OS and PFS) or RR (for
ORR) for dabrafenib plus trametinib versus vemurafenib
plus cobimetinib was statistically non-significant (Table 3).
For OS and PFS, a HR of 0.94 (95% CI 0.68 − 1.30;
p = 0.7227) and 1.05 (95% CI 0.79 − 1.40; p = 0.730),
respectively, was observed, while ORR had a RR of
0.90 (95% CI 0.74 − 1.10; p = 0.3029) (Table 3). These
p values and CIs for efficacy outcomes suggested compar-
able efficacy profiles for the two combination therapies.
To determine if the crossover might have confounded
the results of the primary ITC, the additional analysis
was conducted using pre-crossover data for COMBI-v
(i.e., April 2014 data cut-off ) and the August 2015 cut-
off for coBRIM. Similar results were shown, i.e., no sig-
nificant difference in HR between the two combination
therapies (HR [95% CI] 0.99 [0.69, 1.41]).
Two other additional subgroup analyses were con-
ducted for OS and PFS outcomes for two subgroup pop-
ulations, namely, patients with normal and elevated
LDH levels at baseline. The ITC results did not show
significant differences between dabrafenib plus trametinib
and vemurafenib plus cobimetinib for either subgroup in
terms of OS (normal LDH levels, HR = 0.95 [95% CI 0.58 −
1.54]; elevated LDH levels, HR = 1.05 [95% CI 0.67 − 1.65])
and PFS (normal LDH levels, HR = 1.05 [95% CI 0.67 −
1.65]; elevated LDH levels, HR = 1.23 [95% CI 0.81 − 1.87]).
Safety
Based on the ITC, the overall toxicity profile of dabrafe-
nib plus trametinib appeared to be better than that of
vemurafenib plus cobimetinib. The incidence of any
treatment-related adverse event (AE) (RR 0.92, 95% CI
0.87 − 0.97; p = 0.0015), incidence of any AE of grade ≥3
(RR 0.71; 95% CI 0.60 − 0.85; p = 0.0002), as well as the
incidences of dose interruption or dose modification (RR
0.77, 95% CI 0.60 − 0.99; p = 0.0471) were all significantly
lower with dabrafenib plus trametinib when compared
with vemurafenib plus cobimetinib (Table 4). There were
no significant differences between dabrafenib plus tra-
metinib and vemurafenib plus cobimetinib with regard
to the incidences of any AE (RR 0.98, 95% CI 0.96 − 1.01;
p = 0.3078), any serious AE (RR 0.84; 95% CI 0.60 − 1.16;
p = 0.2835), or any AE leading to death or the rate of
discontinuation due to an AE (RR 0.62; 95% CI 0.33 −
1.16; p = 0.135) (Table 4).
With regard to individual AEs, some AEs occurred at
a significantly higher incidence with vemurafenib plus
cobimetinib compared with dabrafenib plus trametinib,
Table 2 Baseline characteristics of patients in the COMBI-v and
coBRIM studies
COMBI-v coBRIM
D + T V V + placebo V + C
Intent-to-treat
population
352 352 248 247
Age, median
(range), yr
55(18–91) 54(18–88) 55(25–85) 56(23–88)
Male sex, no. (%) 208(59) 180(51) 140(56) 146(59)
ECOG score, no./total no. (%)
0 248/350(71) 248/352(70) 164/244(67) 184/243(76)
1 102/350(29) 14/352(30) 80/244(33) 58/243(24)
2 0/350 0/352 0/244 1/243(<1)
Metastatic status, no./total no. (%)
M0 14/351(4) 26/351(7) 13(5) 21(9)
M1a 55/351(16) 50/351(14) 40(16) 40(16)
M1b 61/351(17) 67/351(19) 42(17) 40(16)
M1c 221/351(63) 208/351(59) 153(62) 146(59)
Elevated LDH,
no. /total no. (%)
118/351(34) 114/352(32) 104/242(43) 112/242(46)
BRAF mutation, no. /total no. (%)
V600E 312/346(90) 317/351(90) 174/206(84) 170/194(88)
V600K 34/346(10) 34 /351(10) 32/206(16) 24/194(12)
D + T dabrafenib plus trametinib, ECOG Eastern Cooperative Oncology Group,
LDH lactate dehydrogenase, V vemurafenib, V + C vemurafenib plus cobimetinib
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including (in alphabetical order) alopecia, arthralgia,
blurred vision, increased blood creatinine, diarrhea, dry
skin, dysgeusia, increased alanine transaminase (ALT)
and aspartate transaminase (AST), keratosis pliaris, nau-
sea, photosensitivity reaction, pruritus, rash, rash macu-
lopapular, skin papilloma, and sun burn (Table 5). Some
AEs occurred more frequently with dabrafenib plus tra-
metinib compared with vemurafenib plus cobimetinib:
chills, constipation, cough, and pyrexia.
Focusing on individual AEs that were graded as severe
(grade 3 or above), the incidence was in many cases
similar between dabrafenib plus trametinib and vemura-
fenib plus cobimetinib (Table 6). A few AEs occurred
more frequently with vemurafenib plus cobimetinib than
with dabrafenib plus trametinib: increased ALT, in-
creased AST, rash maculopapular, and rash.
Discussion
We applied an established methodology [28] to a simple
network based on two trials that were similar in terms
of patient populations and trial protocol. The compari-
son indicated that dabrafenib plus trametinib had com-
parable efficacy as vemurafenib plus cobimetinib in
patients with BRAF-mutated metastatic melanoma, with
no statistically significant difference in ORR, PFS, and
OS. Comparison of the two combination therapies in
terms of AEs found that dabrafenib plus trametinib was
associated with a better safety profile and a lower
occurrence of AEs. A wide variety of individual AEs oc-
curred more frequently with vemurafenib plus cobimeti-
nib, while fewer occurred more frequently with
dabrafenib plus trametinib. When individual severe AEs
(grade 3 or above) were compared between treatments,
a few occurred more frequently with vemurafenib plus
cobimetinib compared with dabrafenib plus trametinib
(p < 0.05), and no severe AE was observed to occur more
frequently with dabrafenib plus trametinib.
The time-to-event outcomes including OS and PFS
were evaluated using the most recent data cut-offs of
both COMBI-v and coBRIM with different follow-up
duration. Specifically, the duration of follow-up was
19 months for dabrafenib plus trametinib and 15 months
for vemurafenib in COMBI-v, and 20.6 months for
vemurafenib plus cobimetinib and 16.6 months for
vemurafenib in coBRIM. Based on the proportional haz-
ards assumption, it can be assumed that variation in the
follow-up times between the COMBI-v and coBRIM tri-
als had no significant effect on the results.
The COMBI-v trial allowed crossover following IDMC
recommendation, which might have been a confounding
factor for the primary ITC. An additional ITC that was
conducted using pre-crossover data for COMBI-v (April
2014 data cut-off ) and the August 2015 cut-off for
coBRIM showed no difference in OS between the two
combination therapies, suggesting minimal impact of
crossover on the primary ITC.
Table 3 Comparison of efficacy for dabrafenib plus trametinib versus vemurafenib plus cobimetinib
Outcome COMBI-v coBRIM ITC results
D + T V V V + C HR/RRa LCI UCI p value
Overall survival, median (95% CI), months 25.6(22.6 − NR) 18.0(15.6 − 20.7) 17.4(15.0 − 19.8) 22.3(20.3 − NR) 0.94 0.68 1.30 0.7227
Progression-free survival, median (95% CI),
months
12.6(10.7 − 15.5) 7.3(5.8 − 7.8) 7.2(5.6 – 7.5) 12.3(9.5 – 13.4) 1.05 0.79 1.40 0.7300
Overall response rate, no./total no. (%) 226/352(64%) 180/352(51%) 124/248(70%) 172/247(50%) 0.90 0.74 1.10 0.3029
aFor D + T versus V + C; HR is the output for time-to-event outcomes, i.e., overall survival and progression-free survival; RR is the output for overall response rate
CI confidence interval, D + T dabrafenib plus trametinib, HR hazard ratio, NR not reached, RR risk ratio, LCI lower 95% CI, UCI upper 95% CI, V vemurafenib, V + C
vemurafenib plus cobimetinib
Table 4 Comparison of general AEs for dabrafenib plus trametinib versus vemurafenib plus cobimetinib
Incidence, number (%) ITC results
COMBI-v coBRIM
AE type D + T (n = 350) V (n = 349) V (n = 246) V + C (n = 247) RR LCI UCI p value
Any AE 345(98.6) 345(98.9) 240(97.6) 244(98.8) 0.98 0.96 1.01 0.3078
Any serious AE 151(43.1) 136(39.0) 64(26.0) 85(34.4) 0.84 0.60 1.16 0.2835
Any treatment-related AE 320(91.4) 342(98.0) 232(94.3) 237(96.0) 0.92 0.87 0.97 0.0015
AE leading to death 4(1.1) 4(1.2) 3(1.2) 5(2.0) 0.60 0.08 4.35 0.6137
Any grade ≥3 AE 199 (56.9) 232 (66.5) 146 (59.4) 176 (71.3) 0.71 0.60 0.85 0.0002
Any dose interruptions/modifications 192(54.9) 197(56.5) 87(35.4) 110(44.5) 0.77 0.60 1.00 0.0471
Discontinuation due to AE 55(15.7) 48(13.8) 20(8.1) 37(15.0) 0.62 0.33 1.16 0.1350
AE adverse event, CI confidence interval, D + T dabrafenib plus trametinib, ITC indirect treatment comparison, RR risk ratio, LCI lower 95% CI, UCI upper 95% CI, V
vemurafenib, V + C vemurafenib plus cobimetinib
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Table 5 Comparison of individual AEs of any grade for dabrafenib plus trametinib versus vemurafenib plus cobimetinib
Incidence, number (%) ITC results
COMBI-v coBRIM
AE type D + T (n = 350) V (n = 349) V (n = 246) V + C (n = 247) RR LCI UCI p value
Abdominal pain 39(11.1) 32(9.2) 19(7.7) 25(10.1) 0.93 0.45 1.91 0.8378
Alopecia 23(6.6) 136(39) 73(29.7) 37(15.0) 0.33 0.19 0.58 0.0001
Anemia 26(7.4) 21(6.0) 20(8.1) 32(13.0) 0.77 0.36 1.67 0.5147
Arthralgia 93(26.6) 182(52.2) 99(40.2) 89(36.0) 0.57 0.42 0.77 0.0003
Asthenia 61(17.4) 58(16.6) 40(16.3) 43(17.4) 0.98 0.59 1.63 0.9368
Blurred vision 17(4.9) 18(5.2) 6(2.4) 25(10.1) 0.23 0.08 0.67 0.0075
Increased blood creatinine 15(4.3) 37(10.6) 20(8.1) 34(13.8) 0.24 0.11 0.52 0.0003
Chills 116(33.1) 28(8.0) 12(5.0)a 20(7.9)# 2.63 1.19 5.82 0.0167
Chorioretinopathy 2(<1) 1(<1) 1(<1) 31(12.6) 0.06 0.00 1.45 0.0843
Constipation 54(15.4) 25(7.2) 26(10.6) 24(9.7) 2.34 1.17 4.68 0.0160
Cough 77(22.0) 40(11.5) 30(12.2) 19(7.7) 3.04 1.59 5.83 0.0008
Cutaneous squamous cell carcinoma 5(1.4) 63(18.1) 27(11.3)a 7(2.8)# 0.32 0.10 1.09 0.0685
Decreased appetite 44(12.6) 70(20.1) 50(20.3) 46(18.6) 0.68 0.42 1.13 0.1361
Dermatitis acneiform 23(6.6) 20(5.7) 22(8.9) 34(13.8) 0.75 0.34 1.61 0.4539
Diarrhea 120(34.3) 136(39.0) 82(33.3) 150(60.7) 0.48 0.36 0.64 <0.0001
Dry skin 33(9.4) 67(19.2) 39(15.9) 35(14.2) 0.55 0.31 0.97 0.0407
Dysgeusia 23(6.6) 47(13.5) 26(10.6) 37(15.0) 0.34 0.18 0.67 0.0018
Edema peripheral 48(13.7) 42(12.0) 28(11.4) 31(12.6) 1.03 0.56 1.91 0.9165
Erythema 35(10.0) 42(12.0) 33(13.4) 24(9.7) 1.15 0.60 2.20 0.6795
Fatigue 110(31.4) 117(33.5) 80(32.5) 85(34.4) 0.89 0.64 1.23 0.4697
Headache 112(32.0) 84(24.1) 39(15.9) 41(16.6) 1.27 0.80 2.03 0.3172
Hyperkeratosis 18(5.1) 89(25.5) 75(30.5) 27(10.9) 0.56 0.30 1.06 0.0734
Hypertension 103(29.4) 82(23.5) 19(7.7) 37(15.0) 0.65 0.36 1.15 0.1399
Increased ALT 49(14.0) 61(17.5) 44(17.9) 65(26.3) 0.54 0.34 0.88 0.013
Increased AST 42(12.0) 46(13.2) 31(12.6) 60(24.3) 0.47 0.27 0.82 0.008
Increased blood ALP 26(7.4) 30(8.6) 22(8.9) 36(14.6) 0.53 0.26 1.08 0.0799
Increased blood CPK 10(2.9) 2(<1) 7(2.9) 80(32.4) 0.44 0.08 2.37 0.3378
Increased GGT 38(10.9) 33(9.5) 44(17.9) 54(21.9) 0.94 0.53 1.66 0.8292
Keratocanthoma 2(<1) 35(10.0) 20(8.4)a 2(<1)# 0.61 0.08 4.58 0.6269
Keratosis pilaris 4(1.1) 48(13.8) 26(10.6) 8(3.2) 0.27 0.08 0.97 0.0442
Myalgia 66(18.8) 56(16.1) 30(12.2) 28(11.3) 1.26 0.71 2.26 0.4298
Nausea 126(36.0) 130(37.3) 62(25.2) 102(41.3) 0.59 0.43 0.82 0.0015
Pain in extremity 45(12.9) 44(12.6) 35(14.2) 24(9.7) 1.49 0.80 2.79 0.2079
Photosensitivity reaction 15(4.3) 81(23.2) 93(37.8) 118(47.8) 0.15 0.08 0.26 <0.0001
Pruritus 36(10.3) 78(22.4) 46(18.7) 48(19.4) 0.44 0.26 0.74 0.0020
Pyrexia 193(55.1) 74(21.2) 56(22.8) 69(27.9) 2.12 1.45 3.09 0.0001
Rash 84(24.0) 150(43.0) 94(38.2) 98(39.7) 0.54 0.39 0.74 0.0001
Rash maculopapular 13(3.7) 28(8.0) 38(15.5) 38(15.4) 0.46 0.22 1.00 0.0490
SCC of skin 2(<1) 21(6.0) 31(12.6) 8(3.2) 0.37 0.07 1.88 0.2310
Skin papilloma 8(2.3) 82(23.5) 29(11.8) 12(4.9) 0.24 0.09 0.62 0.0033
Sun burn 3(<1) 51(14.6) 43(17.5) 34(13.8) 0.07 0.02 0.25 <0.0001
Vomiting 107(30.6) 55(15.8) 31(12.6) 60(24.3) 1.01 0.62 1.64 0.9798
aN = 239; #N = 254
AE adverse event, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, CPK creatine phosphokinase,
GGT gamma-glutamyltransferase, LCI lower 95% CI, RR risk ratio, SCC squamous cell carcinoma, UCI upper 95% CI
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There was some variation in baseline LDH level be-
tween two trials, i.e., COMBI-v had slightly lower pro-
portion of patients with elevated LDH than coBRIM
(i.e., COMBI-v: 34% with dabrafenib plus trametinib and
32% with vemurafenib; coBRIM: 46% with vemurafenib
plus cobimetinib and 43% with vemurafenib). The add-
itional analyses conducted for OS and PFS outcomes in
two subgroup populations, namely patients with normal
and elevated LDH levels, showed similar results as the
primary ITC in overall population. Specifically, there
were no significant differences between dabrafenib plus
trametinib and vemurafenib plus cobimetinib for OS
and PFS within the subgroup populations defined ac-
cording to the baseline LDH levels, suggesting that the
overall results were not confounded by variation in the
distribution of baseline LDH levels.
The advantage of following the method outlined by
Bucher et al. [28] is that the randomization of the indi-
vidual studies is partially retained. Nonetheless, the evi-
dence provided by an ITC is not as strong as that
provided by a direct randomized head-to-head trial be-
tween the two treatments; the evidence should be con-
sidered with this in mind and interpreted with caution.
Additionally, concern has been expressed about the suit-
ability of using ITC to compare safety data, due to their
non-dichotomous nature. However, it should be noted
that health technology agencies such as the French
Haute Autorité de Santé and the Agency for Healthcare
Research and Quality recommend the use of Bucher’s
ITC method for both efficacy and safety outcomes. Add-
itionally, one study has been published using this method
when indirectly comparing safety outcomes [31].
Table 6 Comparison of individual AEs of >grade 3 for dabrafenib plus trametinib versus vemurafenib plus cobimetinib
Incidence (% patients) ITC results
COMBI-v coBRIM
AE type D + T (n = 350) V (n = 349) V (n = 239) V + T (n = 254) RR LCI UCI p value
Alopecia 0(0) 1(<1) 1(<1) 1(<1) 0.35 0.01 24.22 0.6295
Anemia 7(2.0) 4(1.2) 6(2.4) 4(1.6) 2.63 0.46 15.10 0.2787
Arthralgia 3(<1) 15(4.3) 12(4.9) 6(2.4) 0.40 0.08 1.91 0.2513
Asthenia 5(1.4) 4(1.2) 3(1.2) 5(2.0) 0.75 0.11 5.17 0.7711
Cutaneous squamous cell
carcinoma
5(1.4) 62(17.8) 27(11.3) 6(2.4) 0.38 0.11 1.34 0.1337
Dermatitis acneiform 0(0) 4(1.2) 3(1.2) 6(2.4) 0.06 0.00 1.40 0.0792
Diarrhea 4(1.1) 2(<1) 2(<1) 16(6.5) 0.25 0.03 2.34 0.2242
Fatigue 4(1.1) 7(2.0) 7(2.9) 10(4.1) 0.40 0.09 1.88 0.2459
Hyperkeratosis 0(0) 2(<1) 6(2.4) 0(0) 2.60 0.04 169.50 0.6534
Hypertension 54(15.4) 33(9.5) 6(2.4) 11(4.5) 0.89 0.31 2.58 0.8353
Increased ALT 9(2.6) 15(4.3) 15(6.1) 28(11.3) 0.32 0.12 0.88 0.0280
Increased AST 5(1.4) 9(2.6) 5(2.0) 21(8.5) 0.13 0.03 0.56 0.0062
Increased blood ALP 7(2.0) 5(1.4) 4(1.6) 10(4.1) 0.56 0.11 2.82 0.4826
Increased blood CPK 6(1.7) 1(<1) 0(0) 28(11.3) 0.11 0.00 3.49 0.2076
Increased GGT 19(5.4) 17(4.9) 25(10.2) 32(13.0) 0.87 0.39 1.96 0.7436
Keratocanthoma 2(<1) 35(10.0) 20(8.1) 3(1.2) 0.38 0.06 2.44 0.3091
Maculopapular rash 2(<1) 13(3.7) 13(5.3) 17(6.9) 0.12 0.02 0.61 0.0105
Myalgia 0(0) 4(1.2) 6(2.4) 1(<1) 0.67 0.02 24.45 0.8258
Nausea 1(<1) 1(<1) 2(<1) 2(<1) 0.53 0.02 11.65 0.6871
Pain in extremity 4(1.1) 2(<1) 6(2.4) 3(1.2) 4.00 0.45 35.40 0.2121
Photosensitivity reaction 0(0) 1(<1) 0(0) 7(2.8) 0.02 0.00 1.62 0.0820
Pyrexia 16(4.6) 2(<1) 0(0) 4(1.6) 0.94 0.04 24.60 0.9712
Rash 3(<1) 30(8.6) 14(5.7) 13(5.3) 0.11 0.03 0.43 0.0017
SCC of skin 2(<1) 20(5.7) 31(12.6) 7(2.8) 0.44 0.08 2.32 0.3349
Vomiting 4(1.1) 3(<1) 3(1.3) 3(1.2) 0.94 0.09 9.60 0.9598
AE adverse event, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, CPK creatine phosphokinase,
GGT gamma-glutamyltransferase, LCI lower 95% CI, RR risk ratio, SCC squamous cell carcinoma, UCI upper 95% CI
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Consideration should also be given to the fact that
while the ITC indicates a better safety profile of dabrafe-
nib plus trametinib in terms of the frequency of adverse
events, this may not translate into a real-world patient
experience, where, for example, certain grade 2 adverse
events may have a greater impact on a patient’s quality
life than a grade 3-elevated AST/ALT. The safety results
presented in this manuscript should therefore be inter-
preted with caution until data from a direct head-to-
head trial can provide further insights for physicians.
Additionally, COMBI-v and co BRIM trials had different
levels of dose interruptions/modifications this may have
impacted on the severity of toxicity profiles experienced
in both studies.
Conclusions
In conclusion, in the absence of direct, head-to-head
treatment comparisons, ITCs such as the one conducted
in this study provided useful information for physicians
when evaluating available options of BRAF/MEK inhibi-
tor combinations in order to choose the most suitable
treatment for patients, albeit with an understanding of
the limitations of such an analysis. The ITC that com-
pared dabrafenib plus trametinib with vemurafenib plus
cobimetinib suggested similar efficacies between two
combination therapies but reduced adverse events asso-
ciated with dabrafenib plus trametinib.
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